190 related articles for article (PubMed ID: 31468114)
21. Increased placenta growth factor mRNA level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma.
Cheng SJ; Cheng SL; Lee JJ; Chen HM; Chang HH; Kok SH; Chiang ML; Kuo MY
J Formos Med Assoc; 2013 May; 112(5):253-8. PubMed ID: 23660220
[TBL] [Abstract][Full Text] [Related]
22. Evidence based demonstration of the concept of 'field cancerization' by p53 expression in mirror image biopsies of patients with oral squamous cell carcinoma - an immunohistochemical study.
Hande AH; Mohite DP; Chaudhary MS; Patel M; Agarwal P; Bohra S
Rom J Morphol Embryol; 2015; 56(3):1027-33. PubMed ID: 26662135
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of T Lymphoma Invasion and Metastasis 1 (TIAM1) expression in oral squamous cell carcinoma.
Lin L; You J; Qian Y; Han Y; Xiong H; Zhu T; Xia K; Su T
J Biochem Mol Toxicol; 2017 Apr; 31(4):. PubMed ID: 27862620
[TBL] [Abstract][Full Text] [Related]
24. Intratumoural heterogeneity and clone evolution of oral squamous cell carcinoma.
Wang L; Wang X; Jia Y; Guo F; Zhengjun S; Shao Z
Mol Carcinog; 2021 Nov; 60(11):758-768. PubMed ID: 34432915
[TBL] [Abstract][Full Text] [Related]
25. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma.
Lo Muzio L; Leonardi R; Mariggiò MA; Mignogna MD; Rubini C; Vinella A; Pannone G; Giannetti L; Serpico R; Testa NF; De Rosa G; Staibano S
Histol Histopathol; 2004 Jan; 19(1):119-28. PubMed ID: 14702179
[TBL] [Abstract][Full Text] [Related]
26. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management.
Kunkel M; Förster GJ; Reichert TE; Jeong JH; Benz P; Bartenstein P; Wagner W; Whiteside TL
Cancer; 2003 Nov; 98(10):2257-65. PubMed ID: 14601097
[TBL] [Abstract][Full Text] [Related]
27. Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review).
Pekarek L; Garrido-Gil MJ; Sánchez-Cendra A; Cassinello J; Pekarek T; Fraile-Martinez O; García-Montero C; Lopez-Gonzalez L; Rios-Parra A; Álvarez-Mon M; Acero J; Diaz-Pedrero R; Ortega MA
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859591
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Fang CY; Lin YH; Chen CL
J Oral Pathol Med; 2019 Sep; 48(8):712-719. PubMed ID: 31237374
[TBL] [Abstract][Full Text] [Related]
29. [Detection of TP53-mutations in brush biopsies from oral leukoplakias].
Scheifele C; Schlechte H; Bethke G; Reichart PA
Mund Kiefer Gesichtschir; 2002 Nov; 6(6):410-4. PubMed ID: 12447653
[TBL] [Abstract][Full Text] [Related]
30. End Binding 1 (EB1) overexpression in oral lesions and cancer: A biomarker of tumor progression and poor prognosis.
Kumar M; Mehra S; Thakar A; Shukla NK; Roychoudhary A; Sharma MC; Ralhan R; Chauhan SS
Clin Chim Acta; 2016 Aug; 459():45-52. PubMed ID: 27208742
[TBL] [Abstract][Full Text] [Related]
31. Presence of tumour high-endothelial venules is an independent positive prognostic factor and stratifies patients with advanced-stage oral squamous cell carcinoma.
Wirsing AM; Rikardsen OG; Steigen SE; Uhlin-Hansen L; Hadler-Olsen E
Tumour Biol; 2016 Feb; 37(2):2449-59. PubMed ID: 26383526
[TBL] [Abstract][Full Text] [Related]
32. p53 immunoexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management.
Cruz IB; Meijer CJ; Snijders PJ; Snow GB; Walboomers JM; van Der Waal I
J Pathol; 2000 Jun; 191(2):132-7. PubMed ID: 10861571
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
34. ZEB1 as an indicator of tumor recurrence for areca quid chewing-associated oral squamous cell carcinomas.
Ho CM; Hu FW; Lee SS; Shieh TM; Yu CH; Lin SS; Yu CC
J Oral Pathol Med; 2015 Oct; 44(9):693-8. PubMed ID: 25367287
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of pretreatment serum interleukin-6 and tumour necrosis factor alpha as a potential biomarker for recurrence in patients with oral squamous cell carcinoma.
Skrinjar I; Brailo V; Vidovic-Juras D; Vucicevic-Boras V; Milenovic A
Med Oral Patol Oral Cir Bucal; 2015 Jul; 20(4):e402-7. PubMed ID: 25858079
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive mediators of oral squamous cell carcinoma in tumour samples and saliva.
Gonçalves AS; Arantes DA; Bernardes VF; Jaeger F; Silva JM; Silva TA; Aguiar MC; Batista AC
Hum Immunol; 2015 Jan; 76(1):52-8. PubMed ID: 25500427
[TBL] [Abstract][Full Text] [Related]
37. Comparison of morphologic features and outcome of resected recurrent and nonrecurrent squamous cell carcinoma of the penis: a study of 81 cases.
Chaux A; Reuter V; Lezcano C; Velazquez EF; Torres J; Cubilla AL
Am J Surg Pathol; 2009 Sep; 33(9):1299-306. PubMed ID: 19471153
[TBL] [Abstract][Full Text] [Related]
38. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
39. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma.
Girod SC; Pfeiffer P; Ries J; Pape HD
Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452
[TBL] [Abstract][Full Text] [Related]
40. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
